Organization Overview
Timeline
Active Ingredients
Indications
Clinical Trials
Targets and Mechanisms
imiquimod (aldara) (1 trial)
dabrafenib (tafinlar) (1 trial)
denosumab (prolia) (1 trial)
ipilimumab (yervoy) (2 trials)
nivolumab (opdivo) (2 trials)
trametinib (mekinist) (1 trial)
Brain Neoplasms (Phase 2)
Hutchinson's Melanotic Freckle (Phase 3)
Lentigo (Phase 3)
Melanoma (Phase 2)
Neoplasm Metastasis (Phase 2)
Neoplasms, Second Primary (Phase 2)
Trials (4 total)
Trial APIs (6 total)